Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT00006372
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • gemcitabine hydrochloride — DRUG
    Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
  • pegylated liposomal doxorubicin hydrochloride — DRUG
    Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
  • vinorelbine ditartrate — DRUG
    Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.

Key Dates

Start date
Feb 29, 2000
Status verified
Jun 2010
Primary completion
Apr 30, 2003
Completion
Feb 28, 2005

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer CenterClevelandOhio44106-5055-

Find similar trials in Cleveland, OH

By research site
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center· Cleveland, OH

Related Studies